Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cycloastragenol in prevention and treatment of myocardial fibrosis

A technique for myocardial fibrosis and cycloastragalus, which is applied in the field of biomedicine, can solve problems such as cycloastragalol that have not been reported in research, achieve great application prospects, and inhibit the increase of myocardial collagen volume fraction.

Inactive Publication Date: 2018-12-14
PEKING UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] So far, there is no research report on whether cycloastragenol is the active unit of astragaloside IV in inhibiting myocardial fibrosis, and there is no report on the use of cycloastragenol in the treatment of myocardial fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cycloastragenol in prevention and treatment of myocardial fibrosis
  • Application of cycloastragenol in prevention and treatment of myocardial fibrosis
  • Application of cycloastragenol in prevention and treatment of myocardial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1, cycloastragenol (CAG) on isoproterenol (ISO) induced mouse myocardial fibrosis protective experiment

[0057] Experimental mice: 10-week-old male BALB / c mice (average body weight 20 g).

[0058] 1. The experimental mice were randomly divided into the following 4 groups (5 in each group) for the experiment:

[0059] Normal control group: for 7 consecutive days, 0.9% (mass percentage) NaCl aqueous solution was used for gavage (200 μL / rat) every day.

[0060] Model group: for 7 consecutive days, subcutaneously inject isoproterenol ISO (5 mg / kg) to the back of the experimental mice every day, and at the same time use 0.9% (mass percentage) NaCl aqueous solution to gavage (200 μ L / mouse) every day.

[0061] Cycloastragenol low-dose group: for 7 consecutive days, subcutaneously inject isoproterenol ISO (5 mg / kg) to the back of the experimental mice every day, and adopt cycloastragenol (CAG) for gavage every day simultaneously, and cycloastragenol is dissolved in 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of cycloastragenol in prevention and treatment of myocardial fibrosis. The cycloastragenol is applied to one of the following steps (a1) and (a2): (a1) preparinga product for preventing and / or treating myocardial fibrosis; (a2) preventing and / or treating myocardial fibrosis. The cycloastragenol can effectively inhibit a myocardial collagen volume fraction increase, an expression level increase of myocardial fibrosis marker genes in myocardial tissues, an mRNA expression level increase of ANF genes in myocardial tissues, an expression level increase of related inflammatory cytokine genes and the degree of infiltration of inflammatory cells in the heart of the body due to the myocardial fibrosis, and the symptom of irritating dry cough does not occur in experiments of the cycloastragenol. In summary, the cycloastragenol plays an important role in preventing and treating the myocardial fibrosis, and has a great application prospect in the preventionand treatment of the myocardial fibrosis.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of cycloastragenol in preventing and treating myocardial fibrosis. Background technique [0002] Myocardial fibrosis (MF) is caused by a variety of pathological factors and is characterized by excessive proliferation of interstitial fibroblasts in myocardial tissue, excessive deposition and abnormal distribution of collagen fibers, and a significant increase in collagen volume fraction. structure. Myocardial fibrosis is closely related to various cardiovascular diseases such as ischemic cardiomyopathy, hypertensive heart disease, dilated cardiomyopathy and hypertrophic cardiomyopathy. incentive. Fibrotic myocardial stiffness increases, compliance decreases, contractility decreases, and synchronization decreases, making the heart function gradually decline. Fibrosis provides an important structural basis for the occurrence of arrhythmia, and finally gradually turns int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P9/00A61P9/04
CPCA61K31/58
Inventor 祁荣徐璐万雨努尔比耶·图尔迪
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com